

ONCOCYTE TO PARTICIPATE AT THE LAKE STREET 6TH ANNUAL BEST IDEAS **GROWTH CONFERENCE**

Aug 31, 2022

IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdag: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that its management team will participate at the Lake Street 6th Annual Best Ideas Growth Conference on Wednesday, September 14, 2022 at the Yale Club in New York City, NY.

About Oncocyte

Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company's tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermalO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company's pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte's pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx[™], DetermalO[™], DetermaTx[™], DetermaCNI[™], DetermaMx[™] and VitaGraft[™] are trademarks of Oncocyte Corporation.

Investor & Media Contact

Caroline Corner ICR Westwicke Tel: 415.202.5678

caroline.corner@westwicke.com



Source: Oncocyte Corporation

